We serve Chemical Name:ethyl 4-phenylbutyrate CAS:10031-93-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:ethyl 4-phenylbutyrate
CAS.NO:10031-93-3
Synonyms:Ethyl benzenebutanoate;Ethyl 4-phenyl-Mutanoate;ethyl 4-phenylbutyrate;Ethyl 4-Phenylbutyrate;Butyric acid,4-phenyl-,ethyl ester;4-phenylbutyric acid ethyl ester;ethyl phenylpropionate;4-Phenyl-buttersaeure-aethylester;Benzenebutanoic Acid Ethyl Ester;Ethyl 4-phenylbutanoate
Molecular Formula:C12H16O2
Molecular Weight:192.25400
HS Code:2916399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:276.6ºC at 760mmHg
Density:1.002g/cm3
Index of Refraction:1.496
PSA:26.30000
Exact Mass:192.11500
LogP:2.57240
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Ethyl benzenebutanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ethyl 4-phenylbutanoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl phenylpropionate Use and application,Benzenebutanoic Acid Ethyl Ester technical grade,usp/ep/jp grade.
Related News: Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. ethyl 4-phenylbutyrate manufacturer The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. ethyl 4-phenylbutyrate supplier Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. ethyl 4-phenylbutyrate vendor Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. ethyl 4-phenylbutyrate factory The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.
